DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» LIGHT (protein)
LIGHT (protein)
Download
CD137 Microbead Kit CD137 Microbead + Cells
Antagonist Antibodies Against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound S
TACI:Fc Scavenging B Cell Activating Factor (BAFF) Alleviates Ovalbumin-Induced Bronchial Asthma in Mice
CD134 (OX40) Antibodies, Human for Research Use Only
The Thrombopoietin Receptor : Revisiting the Master Regulator of Platelet Production
Role of ADAM10 and ADAM17 in Regulating CD137 Function
Successful Treatment of CD30+Lymphomatoid Papulosis
FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
CD27 APC Catalog Number(S): 9017-0279-025 (25 Tests), 9017-0279-120 (120 Tests)
B-Cell Development, Activation, and Differentiation
B-Cell Maturation Antigen Expression Across Hematologic Cancers: a Systematic Literature Review
BD Pharmingen™ PE-Cy™5 Mouse Anti-Human CD134
(ITP)—Focus on Thrombopoietin Receptor Agonists
Misfolded Proteins Bind and Activate Death Receptor 5 to Trigger
B-Cell Activating Factor (BAFF) in Systemic Lupus Erythematosus, Rheumatoid Arthritis, and Behçet’S Disease
A Small Peptide Antagonist of the Fas Receptor Inhibits Neuroinflammation
Targeting TRAIL-Rs in KRAS-Driven Cancer Silvia Von Karstedt 1,2,3 and Henning Walczak2,4,5
Top View
CD137+ T-Cells: Protagonists of the Immunotherapy Revolution
BAFF and APRIL Expression in B Cells in Vitro and in Vivo
Fas Ligand, Death Gene
BD Horizon™ BV786 Mouse Anti-Human CD27 Antibody (Cat
Monoclonal Anti-Fas Ligand (F2928)
Thrombopoietin Receptor Agonist Therapy in Primary Immune
The Thrombopoietin Receptor: Structural Basis of Traffic and Activation by Ligand, Mutations, Agonists, and Mutated Calreticulin
B-Cell Maturation Antigen (BCMA) As a Target for New Drug Development in Relapsed And/Or Refractory Multiple Myeloma
The Activation of BAFF/APRIL System in Spleen and Lymph Nodes
Anti B-Cell Maturation Antigen CAR T-Cell and Antibody Drug Conjugate Therapy for Heavily Pre-Treated Relapsed and Refractory Multiple Myeloma
Controversy: Blocking Fas Ligand Expression Suppresses Tumor Immune Evasion of Colon Cancer in Vivo
(OX40) Proliferation in the Absence of CD134 Robust B Cell Immunity But
Inhibition of Histone Deacetylase Activity Enhances Fas Receptor-Mediated Apoptosis in Leukemic Lymphoblasts
An Anti-CD30 Chimeric Receptor That Mediates CD3-£-Independent T-Cell Activation Against Hodgkin's Lymphoma Cells in the Presence of Soluble CD301
Mediated Via the Fas/Fas-Ligand System Ultraviolet Light-Induced
An Oral, Nonpeptide Thrombopoietin Receptor Agonist
B Cell Development the Stages of B Cell Development Ordered Gene Rearrangements a Model for Allelic Exclusion the Role of the Pr
Anti-Human CD134 (OX40) APC Catalog Number :16411-80 RUO: for Research Use Only
WEBELOS BADGE REQUIREMENTS (EFFECTIVE DECEMBER 2016) Rank Advancement Is Awarded When Each Scout Has Done the Following: 1
Strong and Selective Glomerular Localization of CD134 Ligand and TNF Receptor-1 in Proliferative Lupus Nephritis
MULPLETA Safely and Effectively
Anticancer Immunity Induced by a Synthetic Tumor-Targeted CD137 Agonist
B‑Cell Activating Factor Receptor Expression Is Associated with Germinal Center B‑Cell Maintenance
Death Receptor 5 (TNFRSF10B)
Ventana Medical Systems, Inc. Jeffrey M. Catania, Ph.D. Regulatory Affairs Director 1910 E. Innovation Park Dr. Tucson, Arizona 87555
CD30+Lymphoproliferations
Importance of TRAIL Molecular Anatomy in Receptor Oligomerization and Signaling
CD137 Receptor by Dendritic Cells Cutting Edge
Antibody Targeting of B-Cell Maturation Antigen on Malignant Plasma Cells
Human Fas Ligand/TNFSF6 Quantikine
Death Receptor 5 Displayed on Extracellular Vesicles Decreases
An Unbiased Screen Identifies a CD137×PD-L1 Bispecific Igg1 Antibody with Unique T-Cell Activation and Binding Properties
B Cell Maturation Antigen–Specific CAR T Cells Are Clinically Active in Multiple Myeloma
BAFF)-R Is the Principal BAFF Receptor Facilitating BAFF Costimulation of Circulating T and B Cells This Information Is Current As of September 23, 2021
Platelet Aggregation Response in Immune Thrombocytopenia Patients Treated with Romiplostim
The Roles of CD137 Signaling in Atherosclerosis
B-Cell-Activating Factor Depletion Ameliorates Aging-Dependent Insulin Resistance Via Enhancement of Thermogenesis in Adipose Tissues
Fas and Fas Ligand Expression in Cystic Fibrosis Airway Epithelium
Therapeutic Expression of an Anti-Death Receptor 5 Single-Chain Fixed-Variable Region Prevents Tumor Growth in Mice
Enhancing the Antitumor Efficacy of a Cell-Surface Death Ligand by Covalent Membrane Display
CD30-Positive Anaplastic Variant of Diffuse Large B-Cell Lymphoma: Frequency and Association with Clinicopathological Parameters